Sunovion Announces Results of Health Outcomes Analyses Exploring the Effectiveness of Aptiom® (eslicarbazepine acetate) in People with Partial-Onset Seizures

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. About Lamprene (Clofazimine) with free prescription (Sunovion) announced results of Health Economics and Outcomes Research (HEOR) analyses from two Phase 3 Aptiom® (eslicarbazepine acetate) monotherapy clinical trials; and a claims analysis of a large database of patients with epilepsy. Buy Minocin (Minocycline) without Rx The results were presented during the 69th American Epilepsy Society (AES) Annual Meeting in Philadelphia. In August 2015, Sunovion announced that the U.S. Diabecon () with free Rx Food and Drug Administration (FDA) approved the use of APTIOM as monotherapy for the treatment of partial-onset seizures. Iobet without prescription APTIOM may be used as monotherapy in people who initiate treatment for the first time or convert from other antiepileptic drugs (AEDs) to APTIOM. A post-hoc pooled analysis of two historical-controlled Phase 3 APTIOM monotherapy clinical trials (Studies 093-045 and 093-046) showed that patients with partial-onset seizures who achieved a clinical response after converting from a multi-AED regimen to APTIOM monotherapy experienced quality of life improvements after 10 weeks. Buy Calan Sr (Verapamil) with free prescription A separate analysis of these studies also showed that patients with partial-onset seizures experienced statistically and clinically significant improvements in depressive symptoms after 10 weeks, following successful conversion from their current AED regimen to APTIOM monotherapy. During AES, Sunovion also presented an analysis from the IMS PharMetrics Plus database. Buy Hypoallergenic Vitamin C online The results indicated that, after controlling for baseline confounders, patients initiating AED therapy with one pill/day had fewer annual hospitalizations and emergency room visits than initiating AED therapy with two or more pills/day. “Seizures account for one million emergency department visits every year, and epilepsy has significant impacts on a person’s ability to drive or maintain employment,” said Krithika Rajagopalan, Head of Global Health Economics and Outcomes Research, Sunovion. http://medicalquestionanswers.wordpress.com “Quality of life assessments provide insights into measurable factors that are important in determining potential treatment outcomes. These results suggest improved seizure control with AED monotherapy is correlated with overall improvements in specific aspects of daily life, as well as fewer hospitalizations. Sunovion is committed to providing health outcomes data that may contribute to improved treatment approaches for people living with partial-onset seizures.” Summary of Highlighted HEOR Poster Presentations Quality of Life Improvement among Patients with Refractory Partial-Onset Seizures: A Clinical Trial Analysis of Patients who Responded to Eslicarbazepine Acetate Monotherapy (Poster 1.182, Presented Saturday, December 5, 2015, 12:00 p.m. – 6:00 p.m. ET) Pooled data from two historical-controlled Phase 3 studies (093-045 and 093-046) evaluated patients who had completed 10 weeks of APTIOM monotherapy (n=224) for change in health-related quality of life, using Quality of Life in Epilepsy-31 (QOLIE-31) questionnaire. The QOLIE-31 is an instrument that assesses daily functioning and overall well-being in patients with epilepsy. The mean change in QOLIE-31 Total Score and seven subscale scores from baseline to Week 18 were compared to standard minimal clinically-important difference (MCID) change scores. The results showed that the mean change in QOLIE-31 Total Score and five of the seven subscales (Medication Effects, Seizure Worry, Social Functioning, Overall Quality of Life, Cognitive Functioning, and Energy/Fatigue) were greater than their respective MCIDs; these changes were statistically significant for Medication Effects (p=0.011), and Social Functioning (p=0.008). Change in Depressive Symptoms Among Patients With Refractory Partial-Onset Seizures Treated With Eslicarbazepine Acetate Monotherapy: A Pooled Analysis of Clinical Trials (Poster 2.249, Presented Sunday, December 6, 8:00 a.m. – 4:00 p.m. ET) Pooled data from two historical-controlled Phase 3 studies (093-045 and 093-046) evaluated patients who had completed 10 weeks of APTIOM monotherapy (Completers, n=224), as well as a subset of these patients who achieved a clinical response after 10 weeks of treatment (Responders, n=117), for change in depressive symptoms, using the Montgomery-Asberg Depression Rating Scale (MADRS) questionnaire. The MADRS is a 10-item instrument used to identify moderate-to-severe depressive symptoms. MADRS scores were compared to 1) Population-level MCID change scores (range: 1.3 to 1.6); and 2) Treatment effect MCID change scores (1 point versus active treatment or 2 points versus placebo). Data showed that mean change in the MADRS scores was significantly decreased (indicating a reduction in depressive symptoms) and exceeded published MCID change scores (-2.1 for Completers and -2.6 for Responders, p<0.001 for both). Over half of all patients in these groups (56.3 percent of Completers and 56.4 percent of Responders) experienced significant reductions in depressive symptoms—with most patients (90.5 percent and 87.9 percent, respectively) reporting decreased MADRS scores of two or more points. The Association Between Antiepileptic Drug Pill Burden at Monotherapy Initiation and Epilepsy-Related Hospital Admissions and Emergency Department Visits in the US (Poster 2.282, Presented Sunday, December 6, 8:00 a.m. – 4:00 p.m. ET) A retrospective analysis of health insurance claims data from more than 53,000 epilepsy patients who initiated AED monotherapy found that patients who initiated with a one pill/day regimen had fewer hospitalizations and emergency room visits over the following 12 months compared with patients initiating with two or more AEDs. Patients initiating with two, three, or more than three pill/day regimens had annual hospitalization rates that were 12.5, 23.1, and 19.4 percent higher respectively, compared to patients taking one pill/day. Patients initiating with larger pill burdens also had significantly higher rates of emergency room visits during the year of following-up (15.5 , 25.2, and 15.1 percent higher for patients taking two, three, or more than three pills/day, respectively). About the Phase 3 Monotherapy Studies Two identically designed Phase 3, dose-blinded, historical-controlled, multi-center, randomized clinical trials (Studies 093-045 and 093-046) evaluated the safety and efficacy of APTIOM (1,600 mg/day or 1,200 mg/day) as monotherapy for partial-onset seizures in patients 16 years of age or older whose seizures were not well-controlled with other antiepileptic drugs (AEDs). The primary endpoint for both trials was the percentage of patients who exited the study due to pre-defined criteria identifying worsening seizure control, compared to historical controls from previous, similarly designed trials of epilepsy patients converting to AED monotherapy. Trial results showed that conversion to APTIOM monotherapy was associated with exit rates superior to historical controls in patients with partial-onset seizures, who were not well-controlled by one or two current AEDs. APTIOM administered once-daily was generally well tolerated in both dose strengths. In the APTIOM monotherapy trials, the most common treatment-related adverse events, headache, dizziness, fatigue, somnolence, and nausea, were mainly mild or moderate in severity. About Aptiom® (eslicarbazepine acetate) APTIOM is the latest member of the dibenzazepine carboxamide family of antiepileptic drugs (AEDs), an established class of medicines. APTIOM is the only exclusively once-daily, non-extended release AED now FDA-approved for use as monotherapy or adjunctive therapy for partial-onset seizures. The precise mechanism(s) by which eslicarbazepine, the primary active metabolite of APTIOM, exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels. APTIOM can be taken whole or crushed, with or without food. APTIOM is not classified as a controlled substance by the FDA. The initial research and development of eslicarbazepine acetate was performed by BIAL-Portela & Ca, S.A. (BIAL), a privately held Portuguese research-based pharmaceutical company. Subsequently, Sunovion acquired the rights under an exclusive license to further develop and commercialize eslicarbazepine acetate in the United States and Canada markets from BIAL. BIAL gained approval for eslicarbazepine acetate from the European Medicines Agency on April 21, 2009 as adjunctive therapy in adult patients with partial-onset seizures with or without secondary generalization. In Europe, the product is marketed under the trade name Zebinix®. APTIOM is approved in Canada for use as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy. About Epilepsy and Partial-Onset Seizures Epilepsy is the fourth most common neurological condition, and one in 26 people in the U.S. will develop epilepsy in his or her lifetime.i Epilepsy manifests as unprovoked seizures, which are caused by abnormal firing of impulses from nerve cells in the brain.ii Partial-onset seizures, the most common type of seizure, are characterized by bursts of electrical activity that are initially focused in specific areas of the brain and may become more widespread, with symptoms varying according to the affected areas.iii The unpredictable nature of seizures may have a significant impact on those with epilepsy. Reducing the frequency of seizures may lessen the burden of epilepsy.ii With approximately one-third of people living with epilepsy still unable to control seizures, there continues to be a need for new therapies.iv Up to 40 percent of people living with epilepsy do not respond to the first or second monotherapyv, and approximately 36 percent fail to achieve adequate control of seizures despite the use of two or more antiepileptic medicationsvi. Please see Important Safety Information below. INDICATION: Aptiom® (eslicarbazepine acetate) is a prescription medicine used alone or with other medicines to treat partial-onset seizures. IMPORTANT SAFETY INFORMATION: Do not take APTIOM if you are allergic to eslicarbazepine acetate, any of the other ingredients in APTIOM, or oxcarbazepine. Suicidal behavior and ideation: APTIOM may cause suicidal thoughts or actions, depression, or mood problems. Call your doctor right away if you experience these or any other effects or reactions: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood. Allergic reactions: APTIOM may cause serious skin rash or other serious allergic reactions that may affect organs or other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your doctor right away if you experience any of the following symptoms: swelling of the face, eyes, lips, or tongue; trouble swallowing or breathing; hives; fever, swollen glands, or sore throat that do not go away or come and go; painful sores in the mouth or around your eyes; yellowing of the skin or eyes; unusual bruising or bleeding; severe fatigue or weakness; severe muscle pain; or frequent infections or infections that do not go away. Low salt (sodium) levels in the blood: APTIOM may cause the level of sodium in your blood to be low. Symptoms may include nausea, tiredness, lack of energy, irritability, confusion, muscle weakness or muscle spasms, or more frequent or more severe seizures. Some medicines can also cause low sodium in your blood. Be sure to tell your healthcare provider about all the other medicines that you are taking. Nervous system problems: APTIOM may cause problems that can affect your nervous system, including dizziness, sleepiness, vision problems, trouble concentrating, and difficulties with coordination and balance. APTIOM may slow your thinking or motor skills. Do not drive or operate heavy machinery until you know how APTIOM affects you. Liver problems: APTIOM may cause problems that can affect your liver. Symptoms of liver problems include yellowing of your skin or the whites of your eyes, nausea or vomiting, loss of appetite, stomach pain, or dark urine. Most common adverse reactions: The most common side effects in patients taking APTIOM include dizziness, sleepiness, nausea, headache, double vision, vomiting, feeling tired, problems with coordination, blurred vision, and shakiness. Drug interactions: Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. Taking APTIOM with certain other medicines may cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Especially tell your healthcare provider if you take oxcarbazepine, carbamazepine, phenobarbital, phenytoin, primidone, clobazam, omeprazole, simvastatin, rosuvastatin, or birth control medicine. Discontinuation: Do not stop taking APTIOM without first talking to your healthcare provider. Stopping APTIOM suddenly can cause serious problems. Pregnancy and lactation: APTIOM may cause your birth control medicine to be less effective. Talk to your healthcare provider about the best birth control method to use. APTIOM may harm your unborn baby. APTIOM passes into breast milk. Tell your healthcare provider if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You and your healthcare provider will decide if you should take APTIOM. If you become pregnant while taking APTIOM, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334. Get medical help right away if you have any of the symptoms listed above. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit .fda.gov/medwatch or call 1-800-FDA-1088. For more information, please see the APTIOM Medication Guide and Full Prescribing Information. About Sunovion Pharmaceuticals Inc. (Sunovion) Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions. Sunovion’s track record of discovery, development and commercialization of important therapies has included Brovana® (arformoterol tartrate), Latuda® (lurasidone HCI), and most recently Aptiom® (eslicarbazepine acetate). Headquartered in Marlborough, Mass. Sunovion is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the Company’s web sites: .sunovion.com, .sunovion.eu and .sunovion.ca. Connect with Sunovion on Twitter @Sunovion and LinkedIn. BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc. LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. APTIOM is under license from BIAL. © 2015 Sunovion Pharmaceuticals Inc. For a copy of this release, visit Sunovion’s web site at .sunovion.com References i Institute of Medicine (IOM). 2012. “Epilepsy across the spectrum: Promoting health and understanding.” Washington, DC: The National Academies Press. ii National Institutes of Health. “NINDS Epilepsy Information Page” Accessed July 2015. <.ninds.nih.gov/disorders/epilepsy/epilepsy.htm> iii Epilepsy Foundation. “Complex Partial Seizures.” Accessed July 2015. <.epilepsy.com/learn/types-seizures/complex-partial-seizures>. iv Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548-1554. v Kwan P, Brodie MJ. “Early Identification of Refractory Epilepsy.” New England Journal of Medicine (2000): 342(5):314-9. .ncbi.nlm.nih.gov/pubmed/10660394. vi Epilepsy Foundation. “Epilepsy Foundation Position Statement” <.epilepsycolorado.org/index.php?s=12105>. Accessed June 2015.

Helius Medical Technologies Announces Positive Clinical Trial Results from its Multiple Sclerosis Pilot Study

. http://mdreview.wordpress.com Buy Gymnema Sylvestre online Buy Cialis Strong Pack-30 () without prescription Buy Ilosone without prescription DDAVP (Desmopressin) with no Rx About Patanol (Olopatadine Hcl) without Rx About Glucophage Xr (Metformin) without Rx

. Buy Gallbladder online Buy Benadryl (Diphenhydramine) without prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/ws7vxt/keloids) has announced the addition of the "Keloids - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://cholesterolreviews.wordpress.com About Helkoss with free prescription Buy Diovan (Valsartan) without prescription It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Buy Decadron (Dexamethason) Buy Renova (Tretinoin) without Rx It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Keloids The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development RXi Pharmaceuticals Corporation Vida Therapeutics Inc. For more information visit .researchandmarkets.com/research/ws7vxt/keloids

Samenvatting Cmed Clinical Services benoemt nieuwe Chief Medical Officer

. Buy Eye Treatment online HORSHAM, Engeland--(BUSINESS WIRE)--Cmed Clinical Services, een innovatieve, full-service CRO die diensten aan de biopharmaindustrie wereldwijd biedt, kondigde vandaag de benoeming aan van Dr. http://cardiobloodreview.wordpress.com Cleocin (Clindamycin) without prescription Bams Abila, MD, PhD, FFPM, Chief Medical Officer. Dr. Super Avana (Avanafil + Dapoxetine) with free Rx Abila zal in deze rol verantwoordelijk zijn voor het leiden van de ontwikkeling en exploitatie van de medische functie van Cmed, door leiderschao en strategische begeleiding te bieden over medische en wetenschappelijke kwesties. About Revia (Naltrexone) with no prescription Hij zal ook algemene ondersteuning en training bieden aan de medische en consultancygroepen binnen Cmed, om veilige, legale, ethische en optimale geneesmiddelontwikkeling en de uitvoering van klinische studies te waarborgen. Dit slimme nieuwsbericht bevat multimedia. About Glinate without prescription Bekijk hier het volledige bericht: .businesswire.com/news/home/20151009005298/en/ Deze bekendmaking is officieel geldend in de originele brontaal. Buy Epivir (Lamivudine) without Rx Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, welke als enige rechtsgeldig is.

Genzyme Introduces “vs.MS,” a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed Care

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, today announced a new global initiative, vs.MS, that is designed to raise awareness of the often unspoken emotional and physical burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. About Benicar Hct (Olmesartan - Hydrochlorothiazide) with no Rx To better understand the full burden associated with RMS, Genzyme fielded a global survey among more than 1,500 people living with RMS and their care partners across seven countries. About Ventolin Inhaler (Albuterol) with free Rx An initial set of data from the vs.MS global survey will be shared for the first time at the 31st Congress of the European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, October 7-10. “As part of our ongoing commitment to help improve the lives of people living with MS, we are proud to introduce this new global initiative in collaboration with patients and caregivers,” said Darlene Jody, Head of MS Medical Affairs at Genzyme. About Diamox (Acetazolamide) “At Genzyme, we believe that when we know more, we can do more. About Fungotek with free prescription The experiences uncovered through the vs.MS survey will help shed light on the physical and emotional toll RMS can have, and we look forward to developing a program that may help drive a more open exchange for better informed care.” While at ECTRIMS, Genzyme is bringing together thought leaders from across the MS Community representing people living with MS, healthcare providers specializing in the disease, and advocacy groups to review the full vs.MS survey findings and begin developing a program that will be rolled out to the community. To unveil the initial vs.MS survey results at ECTRIMS, Genzyme is hosting an interactive digital experience at their booth, as well as sharing the findings via the @GenzymeCorp Twitter handle. Gasex () with no prescription For each individual who participates in the interactive digital experience and for every retweet that includes the campaign hashtag #vsMS, Genzyme will donate 5 Euros to the Multiple Sclerosis International Federation (MSIF) in support of the organization’s research efforts. Data from the vs.MS global survey will provide a glimpse into the impact the disease may have on various aspects of day-to-day life for people living with RMS. Buy Digestion for Pets online For example, half of respondents feel their ability to progress in their career has changed for the worse since they were diagnosed with RMS, and 40 percent are concerned about being able to keep their job. The vs.MS survey also reveals the effect of RMS on the emotional well-being of those living with the disease and their care partners. http://asthmareview.wordpress.com For example, more than half of respondents living with RMS feel lonely or isolated because of their MS, while more than half of care partners do not discuss their fear of MS progressing to avoid upsetting the person they care for. “The results of this global survey offer a unique look into the realities of relapsing MS, including the challenges that people living with MS and their care partners deal with on a daily basis,” said Dr. Barry Singer, MD, Director of The MS Center for Innovations in Care at Missouri Baptist Medical Center in St. Louis, MO, and a vs.MS steering committee member. “We are hopeful that insight into the daily struggles of those living with MS will result in better disease management.” The vs.MS survey was fielded among more than 1,500 people across seven countries, including people living with RMS and RMS care partners. Developed with input and guidance from a steering committee of leading global neurologists specializing in MS, the online survey addressed topics such as progression and disability; cognitive challenges; relationship and intimacy issues; emotional burden; fatigue and sensitivity; bladder and bowel challenges; and impact of MS on careers. In the coming months, Genzyme will reveal the full vs.MS data set and partner with the MS Community to encourage behavior and attitude shifts in an effort to drive better outcomes for those affected by the disease. About Genzyme, a Sanofi Company Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at .genzyme.com. Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved. About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Availability of Medical Abortion in the U.S. Continues to Provide Women Safe Alternative, 15-Years after FDA Approval

WASHINGTON--(BUSINESS WIRE)--This September marks the 15-year anniversary of the U.S. Buy Aldara (Imiquimod) with free prescription Food and Drug Administration (FDA) s approval of the use of Mifepristone (also known as RU-486 or the "abortion pill"). About Zantac (Ranitidine) without prescription Mifepristone is the first and only FDA approved medication to provide women with a safe and effective non-surgical option to end an early pregnancy. “Medication abortion is an empowering, private, and non-invasive procedure that puts the control back in the woman’s hands. About Super Active Pack-40 () without prescription Carafem is proud to focus on the availability of the abortion pill along with a variety of birth control options to provide women choices and support their decisions regarding the timing and spacing of their children,” says Melissa Grant VP of Carafem. Buy Flutex “Women are given Mifepristone in our health center, to be followed by another medication called Misoprostol, usually taken at home the same day or up to 72 hours later. Inderal La (Propranolol) with no prescription Having options for how and when to use these medications allows a woman more flexibility and control around when and where she experiences the abortion process. Buy CoQ10 Supplements online Medication abortion does not require surgery or anesthesia.” The proportion of women in the United States deciding to end a pregnancy by medication has been steadily growing since Mifepristone’s approval. http://doctor-answers.blogspot.com/ Since 2000, more than 2 million women in the United States have chosen medication abortion for ending an early pregnancy. There is overwhelming evidence that medication abortion is safe for virtually all women. Never before has abortion been safer, less invasive and more affordable than with medication abortion and Carafem focuses on the provision of this method for early abortion care. By providing same-day appointments, one-on-one private visits with a knowledgeable clinician, financial assistance, and visits that routinely last no more than an hour, Carafem is responding to a critical need in women’s reproductive healthcare. Medically unnecessary restrictions have contributed to the abortion pill not being as widely available to women as it could be. The reality is that these regulations do nothing to make abortion safer- but they make it more costly and less available. “Carafem is proud to ensure that women are aware of all of their reproductive health care options through education in our health centers and through our honest and cutting-edge advertising campaigns. Carafem aims to lift the stigma that surrounds this common medical procedure,” adds Grant. On the 15th anniversary of Mifepristone’s approval in the U.S., Carafem aims to deflate negativity and increase awareness of something that is, and has been, common in our society. In fact, 1 in 3 women will choose to have an abortion during her reproductive lifetime. This statistic offers cultural validation for updating the conversation and highlights the importance of access to quality health care.

Biogen Prices $6.0 Billion of Senior Unsecured Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the pricing of four series of senior unsecured notes for an aggregate principal amount of $6.0 billion. Buy Zofran (Ondansetron) without prescription The notes will mature as follows: $1.50 billion will mature on September 15, 2020 and will bear interest at an annual rate of 2.900% $1.00 billion will mature on September 15, 2022 and will bear interest at an annual rate of 3.625% $1.75 billion will mature on September 15, 2025 and will bear interest at an annual rate of 4.050% $1.75 billion will mature on September 15, 2045 and will bear interest at an annual rate of 5.200% The offering is expected to close on September 15, 2015, subject to customary closing conditions. Biogen intends to use the net proceeds from this offering, together with cash on hand, to fund share repurchases of its common stock under the company’s previously authorized $5.0 billion share repurchase program, for working capital and other general corporate purposes. Goldman, Sachs & Co. Azulfidine (Sulfasalazine) with no prescription and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint book-running managers and representatives of the several underwriters. Avapro (Irbesartan) with free Rx A copy of the preliminary prospectus supplement and the accompanying base prospectus, which is filed as part of Biogen’s effective shelf registration statement on Form S-3 filed on September 8, 2015 (File No. About Felogard without prescription 333-206799), may be obtained from either of the representatives by calling Goldman, Sachs & Co. About Maxalt (Rizatriptan) toll-free at 1 (866) 471-2526 or Merrill Lynch, Pierce, Fenner & Smith Incorporated toll-free at 1 (800) 294-1322. An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission’s website at .sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or other jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Buy Cat’s Claw online The offering of the notes may be made only by means of a prospectus supplement and the accompanying base prospectus. About BiogenThrough cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. http://future-pharmaceuticals.blogspot.com Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. Biogen Safe Harbor StatementThis press release contains forward-looking statements that involve risks and uncertainties, including statements about the expected use of proceeds and timing of completion of the offering. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. The offering may also be adversely affected by market conditions, adverse changes to Biogen’s business or prospects, and the other risks and uncertainties that are described in Biogen’s filings with the Securities and Exchange Commission. These statements are based on current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements.

Eosinophilic Esophagitis Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles

. About Etoricoxib with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/bgmx8f/eosinophilic) has announced the addition of the "Eosinophilic Esophagitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. About Noroxin (Norfloxacin) Buy Vermox (Mebendazole) with free Rx It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Buy Breast Enhancement online Buy Cialis Daily (Tadalafil) with free prescription It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development Allergan Plc DBV Technologies S.A. Dr. http://medical-questions-answers.blogspot.com Buy Indocin (Indomethacin) Falk Pharma GmbH Novartis AG Receptos, Inc. Regeneron Pharmaceuticals, Inc. Shire Plc Drug Profiles Allergen for Milk Allergy budesonide budesonide dectrekumab dupilumab EUR-1100 Qi-406 RPC-4046 For more information visit .researchandmarkets.com/research/bgmx8f/eosinophilic

Platelet Receptor Inhibitors Pipeline Insights Review 2015

. Buy Precose (Acarbose) with no prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/8sjc6v/platelet_receptor) has announced the addition of the "Platelet Receptor Inhibitors -Pipeline Insights" report to their offering. Platelet Receptor Inhibitors Pipeline Insights provides the in-depth analysis of the pipeline assets across the Platelet Receptor Inhibitors. Buy Bee Pollen online About Suprax (Cefixime) without Rx The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://webmd-board.blogspot.com About Demadex (Torsemide) without Rx The Platelet Receptor Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Platelet Receptor Inhibitors Pipeline Insights Report covers the Platelet Receptor Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. Buy Ceftin (Cefuroxime) without Rx The Report also provides Platelet Receptor Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. About Entocort without Rx The Report also highlights the discontinued and inactive projects in pipeline for Platelet Receptor Inhibitors. Scope - The report provides a Platelet Receptor Inhibitors Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Platelet Receptor Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Platelet Receptor Inhibitors and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/8sjc6v/platelet_receptor

Global Coronary Disease Pipeline Review 2015

. Buy Asthma online About Doxycycline (Doxycycline) with no Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/df9f4k/coronary) has announced the addition of the "Coronary Disease-Pipeline Insights" report to their offering. This Coronary Disease-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. http://webmdmagazine.wordpress.com Buy Emend without prescription About Seromycin (Cycloserine) with free Rx A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Coronary Disease. This report provides information on the therapeutic development based on the Coronary Disease dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. Buy Purim () with no Rx Buy Droxia (Hydroxyurea) without prescription It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Coronary Disease - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Coronary Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Coronary Disease and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/df9f4k/coronary

Verrucous Carcinoma Global Clinical Trials Review, H1, 2015

. Buy Doryx with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/khqfrb/verrucous) has announced the addition of the "Verrucous Carcinoma Global Clinical Trials Review, H1, 2015" report to their offering. "Verrucous Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Verrucous Carcinoma clinical trial scenario. Buy Tadora (Tadalafil ) with no prescription Nexium (Esomeprazole) without Rx This report provides elemental information and data relating to the clinical trials on Verrucous Carcinoma. Buy Vitex online About Keflex (Cephalexin) with no Rx It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. http://webmdconsult.wordpress.com Buy Duphaston (Dydrogesterone) with no Rx The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Verrucous Carcinoma. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies MatrixPharm National Cancer Institute Roswell Park Cancer Institute Fox Chase Cancer Center Ohio State University Comprehensive Cancer Center Radiation Therapy Oncology Group University of Chicago Wake Forest University Abramson Cancer Center AIDS Malignancy Clinical Trials Consortium For more information visit .researchandmarkets.com/research/khqfrb/verrucous

Global Mycoses Pipeline Insights Study 2015

. About Voveran SR (Diclofenac) with free Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/3n73v6/mycosespipeline) has announced the addition of the "Mycoses-Pipeline Insights" report to their offering. Mycoses Pipeline Insights provides the in-depth analysis of the pipeline assets across the Mycoses. Buy Soy Protein online About Imitrex (Sumatriptan) with no Rx The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://pharmaceuticaljournal.wordpress.com Buy Norvir (Ritonavir) without Rx The Mycoses Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Mycoses Pipeline Insights Report covers the Mycoses pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. Suhagra (Sildenafil Citrate) with no Rx The Report also provides Mycoses related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. Desogestrel with free prescription The Report also highlights the discontinued and inactive projects in pipeline for Mycoses. Scope - The report provides a Mycoses Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Mycoses pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Mycoses and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/3n73v6/mycosespipeline

Global Meningitis Pipeline Insights Report 2015

. About Allegra (Fexofenadine) with free Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/v7cf87/meningitispipelin) has announced the addition of the "Meningitis-Pipeline Insights" report to their offering. Meningitis - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Meningitis. Buy R-Lipoic Acid online Detrol La (Tolterodine) without Rx The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://webmd-consult.blogspot.com About Rhinocort (Budesonide) The Meningitis Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Meningitis - Pipeline Insights Report covers the Meningitis pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. Aralen (Chloroquine) with no prescription The Report also provides Meningitis related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. Buy Daclin with free prescription The Report also highlights the discontinued and inactive projects in pipeline for Meningitis. Scope - The report provides a Meningitis Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Meningitis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Meningitis and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/v7cf87/meningitispipelin

ESMO GI provides new insights into HCC and metastatic liver cancer

Studies presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal cancer, Barcelona, Spain,1-4 July, helped define the hepatocellular carcinoma and liver metastatic colorectal cancer patient populations in which established treatments work best and provided insights into emerging therapies. Scientists believe there is an unmet medical need for both hepatocellular carcinoma and metastatic liver cancer. Patients with hepatocellular carcinoma (HCC) have a poor prognosis with median survivals of 10 to 11 months despite use of sorafenib first line. Detrol La (Tolterodine) without Rx Liver metastases develop in nearly 20% of patients with stage II and 50% of patients with stage III colorectal cancer and represent the major cause death in this disease. About Rhinocort (Budesonide) Unfortunately, radical surgical resection of liver metastases is only possible in 10 to 25% of patients with CRC confined to the liver. Aralen (Chloroquine) with no prescription In most patients the number, localization and/or size of the liver metastases or poor hepatic reserve preclude resection. Buy Daclin with free prescription All this points to the unmet medical need for both HCC and metastatic liver cancer. The latest analysis of the GIDEON study, which set out to evaluate the safety of sorafenib in a real world population of HCC patients, showed improved outcomes for patients over 70 years compared to those under 70 years. About Allegra (Fexofenadine) with free Rx The current subgroup analysis explored 278 patients from the Italian cohort of the main study, of whom 141 were older than 70 years and 133 younger. Results showed that the median overall survival was 10 months in the younger age group versus 20 months in the older age group. Buy R-Lipoic Acid online Furthermore, elderly patients had a PFS of 6 months versus 4.1 months for younger patients; and elderly patients had a time to progression of 7.6 months versus 5 months for younger patients. http://webmd-consult.blogspot.com The authors believe that younger patients have shorter overall survivals due to more advanced disease. The latest sub-analysis from the SIRFLOX study showed patients with metastatic colorectal cancer (mCRC) that has spread only to the liver at study entry do better with selective internal radiation therapy (SIRT) than those with more widespread metastases. With SIRT, a technique granted CE Mark approval in the EU in 2002 for unresectable liver tumours, yttrium-9-resin microspheres (Sirtex) are delivered to the liver via a hepatic artery injection. Key to the success of the procedure is occlusion of extra-hepatic vessels to prevent deposition of radioactive microspheres outside the liver. Since there have never been large randomized controlled trials for SIRT in combination with modern first-line standard of care chemotherapy the SIRFLOX study was initiated. Data presented at ASCO 2015 failed to show overall progression free survival advantages for patients treated with mFOLFOX6 + SIRT compared to those treated with chemotherapy alone. The findings were attributed to the inclusion of 40% of patients with extra-hepatic metastatic disease in the analysis. In the current sub-group analysis the investigators explored the 318 patients with metastases limited to the liver at the time they entered the study separately from the 212 patients with both liver and extra hepatic metastases at study entry. Results showed that for those treated with metastases limited to the liver median PFS in the liver was 21.1 months for those treated with chemotherapy + SIRT compared to 12.4 months for those treated with chemotherapy alone (p=0.003, HR 0.64). "These new pre-planned sub-group findings for PFS in the liver should lead oncologists to consider adding SIR-Spheres Y-90 resin microspheres to first-line chemotherapy," said Guy van Hazel, the co-principal investigator of the SIRFLOX study, from the University of Western Australia, Perth. Rose bengal solution as hepatocellular carcinoma treatment According to one intriguing abstract study, a single injection with PV-10 led to the complete disappearance of HCC in one patient, and colorectal liver metastases in another. PV-10, a 10% solution of rose bengal used originally to stain necrotic tissue in the cornea, has been showing promise in melanoma. A phase 2 study, presented at ESMO last year, demonstrated that 50% of patients with stage III melanoma patients who had all their cutaneous lesions injected with PV-10 achieved a complete response. For the current study two cohorts of patients, one with non-resectable HCC (n=6) and a second with other forms of cancer metastatic to the liver (n=7, three originally colorectal tumors, two nonsmall cell lung, two melanoma and one ovarian) underwent a single percutaneous injection of PV-10 guided by CT to one target lesion in the liver at least 1 cm in diameter. From the analysis of the first five patients (who had six tumours injected) the investigators found that two patients showed no evidence of disease at more than 40 months follow-up according to RECIST and EASL criteria. The first patient was a 68 year old male with HCC (hepatitis B and cirrhosis) alive at 54 months follow-up with no evidence of disease; while the second patient was a 61-year-old male with metastatic CRC alive at 42 months follow-up with no evidence of disease. "Having liver cancer patients alive at up to 54 months follow-up with no evidence of disease is remarkable. This is even more extraordinary when you consider these patients received just one or two intralesional injections," says Eric Wachter, the author of the abstract who co-developed PV-10. As with melanoma, the mechanism of PV-10 in liver cancers is believed to be due to local chemoablative effects where the agents enters lysosomes causing tumor necrosis that can stimulate immunological effects. Furthermore, melanoma patients injected with PV-10 have been shown to have increased T cells in peripheral blood, including CD8+, CD4+, CD3+ and NKT. Written by Janet Fricker

People with schizophrenia have more rare genetic mutations

. Buy Pregnenalone online chizophrenia is a common, complex disorder that appears to arise from a number of factors, some of which are genetic. http://medicalquestionanswers.wordpress.com About Coumadin (Warfarin) Now, a new study of the genetic mutations associated with schizophrenia has deepened our understanding of its genetic structure. The DNA screening study found that patients with schizophrenia had more rare variants of genes that code for proteins than people not affected by the condition. The international study, led by the University of California Los Angeles (UCLA), is published in the journal Nature Communications. There, the researchers describe how after screening for hundreds of thousands of genetic variants in people with and without schizophrenia, they found certain types - rare mutations that code for proteins - occur more frequently in people with the condition. First author Dr. Buy Singulair (Montelukast) Loes Olde Loohuis, of UCLA s Center for Neurobehavioral Genetics, says: "While we cannot point to specific mutations that play a causal role in schizophrenia, we show that schizophrenia patients collectively have more of these mutations than unaffected individuals." Mutations in genes that code for proteins play a key role in the development of the brain before birth, notes senior author Roel Ophoff, a professor in psychiatry and human genetics at UCLA, who adds: "Our finding further supports the hypothesis that schizophrenia is a disorder that may originate during the early stages of brain development." Schizophrenia is a common disorder characterized by hallucinations, delusions and disorganization, that can significantly impair quality of life for patients and their families. Buy Herbolax () In the US, around 2-3 million people have the condition. Rare coding variants contribute to complex genetic architecture of schizophrenia Fast facts about schizophrenia Schizophrenia is a condition that affects thinking, feeling and behavior and causes people to have abnormal experiences The condition will affect around 1 in every 100 people in their lifetime Contrary to what many believe, people with schizophrenia are rarely violent - they are more likely to be victims of violence by others. Find out more about schizophrenia For the study, the team used a commercially available DNA screening tool to search for 250,000 coding variants in 1,042 schizophrenia patients from the Netherlands and 961 unaffected individuals. A coding variant is where a gene or sequence of DNA that contains instructions for making a protein is slightly altered, thus raising the chance that the associated protein may cause malfunction in the cell in which it is made. The results of the DNA screening showed that the patients with schizophrenia had more of the variants than patients without schizophrenia. The researchers confirmed these findings in another study group of more than 13,000 people with and without schizophrenia. Prof. About Cyclospasmol without prescription Ophoff says even though we know there is a large genetic component in schizophrenia, we do not know enough about the underlying biology, and concludes: "Our research shows that rare coding variants throughout the human genome also contribute to this complex genetic architecture." In discussing their results, the authors also note that the genes containing rare coding variants "significantly overlap with genes expressed in fetal brain highlighting the potential involvement of neurodevelopment" in the causes of schizophrenia. The National Institute of Mental Health funded the research. This work follows news of another piece of research that Medical News Today reported recently that offers strong evidence of a neurological cause of schizophrenia. Arimidex (Anastrozole) with free Rx Writing in the journal Neuron, a team from the University of Cardiff in the UK describes how they found schizophrenia mutations interfere with chemical signaling in the brain. Written by Catharine Paddock PhD

Food container plastics linked to hypertension

Chemicals supposed to be safe replacements for harmful chemicals in plastics are linked to hypertension and insulin resistance, a precursor to diabetes, find scientists from NYU Langone Medical Center in New York City. Small rises in blood pressure were linked to the chemicals supposed to replace those previously found to be unsafe. The phthalate compounds in question - di-isononyl phthalate (DINP) and di-isodecyl phthalate (DIDP) - are replacements for another chemical, di-2-ethylhexylphlatate (DEHP), which the same researchers proved in previous research to have similar adverse effects. The phthalates are meant to strengthen plastic wraps and processed food containers, among other household items. The two new pieces of research are published in the journals Hypertension and The Journal of Clinical Endocrinology and Metabolism. In the Hypertension study, for every 10-fold increase in the amount of phthalates consumed, there was a 1.1 millimeters of mercury (mmHg) increase in blood pressure. In the other study, one in three adolescents with the highest DINP levels had the highest insulin resistance, while for those with the lowest concentrations of the chemicals, only 1 in 4 had insulin resistance. Growing concerns over environmental chemicals and insulin resistance Study leader Dr. About Avodart (Dutasteride) with free prescription Leonardo Trasande, a professor at NYU Langone, says: "Our research adds to growing concerns that environmental chemicals might be independent contributors to insulin resistance, elevated blood pressure and other metabolic disorders." Prof. Buy Viagra Gold (Sildenafil Citrate + L-Arginine + Giseng + Vitamin B6 + Folic Acid) with no Rx Trasande would like the 1976 Toxic Substances Control Act updated: "Our study adds further concern for the need to test chemicals for toxicity prior to their broad and widespread use, which is not required under current federal law." Other research from Prof. Buy Theo-24 Sr (Theophylline ) with no Rx Trasande in 2013 confirmed a link between DEHP exposure and hypertension in Americans. Buy Combantrin with free Rx DEHP was used as a plasticizer but banned in Europe in 2004 - DINP and DIDP are designed to replace it. Ceclor (Cefaclor) with free Rx Perhaps the safer alternatives lie in not using plastics at all. "Alternatives to DIDP and DINP include wax paper and aluminum wrap; indeed, a dietary intervention that introduced fresh foods that were not canned or packaged in plastic reduced phthalate metabolites substantially." Prof. Buy Neem online Trasande adds that there are "safe and simple" steps that can limit exposure to phthalates, including: Do not microwave food in plastic containers or covered by plastic wrap Do not wash plastic food containers in the dishwasher, where plasticizers can leak out Avoid phthalates by avoiding plastic containers labeled with the numbers 3, 6 or 7 inside the recycle symbol. The results of the research come from blood and urine sample analysis of participants in the National Health and Nutrition Examination Survey (NHANES). Since 1999, NHANES has surveyed 5,000 volunteers annually about risk factors and diseases. http://web-md.blogspot.com As part of the NYU Langone investigation, blood and urine samples were analyzed from a diverse group of children and adolescents aged between 6 and 19 years. Blood and urine samples were collected once between 2008 and 2012, and the study volunteers blood pressure was similarly measured. Diet, physical activity, gender, race/ethnicity, income, and other factors independently associated with insulin resistance and hypertension were also factored into the researchers analysis. Written by Markus MacGill

Weight-loss surgery 'highly effective' for type 2 diabetes remission

A new study suggests weight-loss surgery combined with low-level lifestyle interventions may be a more effective treatment strategy for obese patients with type 2 diabetes than lifestyle interventions alone. While lifestyle interventions alone appear to have no effect on type 2 diabetes remission, researchers found these combined with weight-loss surgery led to remission for many obese patients with the condition. Dr. About Apcalis Oral Jelly (Tadalafil) with no prescription Anita P. Vpxl (Vpxl) with no prescription Courcoulas, of the University of Pittsburgh Medical Center, PA, and colleagues publish their findings in JAMA Surgery. Excess weight is a major risk factor for type 2 diabetes; more than 90% of people who have type 2 diabetes are overweight or obese. It is recommended that obese patients with type 2 diabetes adopt lifestyle changes, such as a healthy diet and regular exercise, to help manage or treat their condition. Prandin (Repaglinide) without prescription But recently, studies have suggested weight-loss surgery, or bariatric surgery, may be just as effective as lifestyle interventions and medical therapy for obese patients with type 2 diabetes In April 2014, for example, Medical News Today reported on a study published in the New England Journal of Medicine that found obese patients who underwent bariatric surgery were able to control their type 2 diabetes without the use of medical therapy in the 3 years following the procedure. But Dr. Clopress without prescription Courcoulas and colleagues say "questions remain" about the efficacy of such treatment. About Cialis Pack-30 () without Rx "More information is needed about the longer-term effectiveness and risks of all types of bariatric surgical procedures compared with lifestyle and medical management for those with T2DM [type 2 diabetes mellitus] and obesity," they note. As such, the team assessed the outcomes of 61 obese patients aged 25-55 with type 2 diabetes who were randomly assigned to receive either weight-loss surgery in the first year followed by a low-level lifestyle intervention for 2 years, or an intense lifestyle intervention for 1 year followed by a low-level lifestyle intervention for 2 years. Subjects who underwent weight-loss surgery received one of two procedures: roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB). Buy Mullein online RYGB involves the creation of a small stomach pouch from a portion of the stomach, which is then connected to the small intestine, bypassing the rest of the stomach and the duodenum. http://cholesterolreviews.wordpress.com LAGB involves the placement of a band around the upper part of the stomach to create a smaller stomach pouch. The band can be adjusted after the procedure to make food pass more slowly or quickly through the stomach. Both of these procedures limit the amount of food a person can eat, making them feel full faster. Dr. Courcoulas and colleagues assessed the incidence of partial or complete type 2 diabetes remission among all subjects after 3 years. Weight-loss surgery led to complete type 2 diabetes remission for some obese patients Bariatric surgery was found to be most effective for weight loss among study participants. Those who underwent RYGB lost around 25% of their body weight during follow-up, LAGB subjects lost around 15% of their body weight, while lifestyle intervention-only participants lost around 5.7%. The team found that many participants who underwent weight-loss surgery followed by lifestyle interventions experienced partial or complete type 2 diabetes remission, while those who engaged in lifestyle interventions alone experienced no remission at all. Of the subjects who underwent RYGB, 40% experienced partial or complete type 2 diabetes remission, while this was the case for 29% of subjects who underwent LAGB. Three subjects treated with RYGB and one treated with LAGB had complete remission. In addition, the team found that patients who underwent weight-loss surgery were more likely to have better blood glucose control and less likely to need medication for their type 2 diabetes, compared with those who engaged in lifestyle interventions alone. "More than two thirds of those in the RYGB group and nearly half of the LAGB group did not require any medications for T2DM treatment at 3 years," say the researchers. One strength of this study, according to the team, is that around 40% of participants fell into the category of class 1 obesity - defined as having a body mass index (BMI) of between 30 and 35. The researchers note that weight-loss surgery is normally carried out on patients with a BMI of 40 or more, so data is lacking on the effects of weight-loss surgery for obese patients with a lower BMI. Commenting on their findings, the team says: "This study provides further important evidence that at longer-term follow-up of 3 years, surgical treatments, including RYGB and LAGB, are superior to lifestyle intervention alone for the remission of T2DM in obese individuals including those with a BMI between 30 and 35. While this trial provides valuable insights, unanswered questions remain such as the impact of these treatments on long-term microvascular and macrovascular complications and the precise mechanisms by which bariatric surgical procedures induce their effects." In an editorial linked to the study, Dr. Michel Gagner, of Florida International University in Miami, says the findings indicate the use of weight-loss surgery should be increased for obese individuals with type 2 diabetes. "We should consider the use of bariatric (metabolic) surgery in all severely obese patients with T2DM and start a mass treatment, similar to what was done with coronary artery bypass graft more than 50 years ago," he says. In November 2014, MNT reported on a study suggesting that weight-loss surgery may also be effective for prevention of type 2 diabetes among obese patients. Published in The Lancet Diabetes & Endocrinology, the study found that obese patients who underwent bariatric surgery were 80% less likely to develop type 2 diabetes than those who received no obesity-related treatment. Written by Honor Whiteman

Traders' testosterone 'makes them take financial risks'

Researchers simulating the financial trading floor in the lab have found that traders hormone levels in the stressful, competitive environment are raised, making them invest in more risky assets. Cortisol is involved in the fight or flight response. The study, published in Scientific Reports, found that when given doses of either cortisol or testosterone, the participants buying and selling assets among themselves invested more in risky assets. They measured the volunteers natural hormone levels in one experiment and artificially raised them in another. About Champix (Varenicline) without Rx "Our view is that hormonal changes can help us understand traders behavior, particularly during periods of financial instability," said Dr. Buy Amoxil (Amoxicillin) without Rx Carlos Cueva, PhD, one of the lead authors of the study, from the department of economics at the University of Alicante, Spain. Cortisol is elevated in response to physical or psychological stress, increasing blood sugar and preparing the body for a fight-or-flight response. The authors suggest their findings could help with the development of more stable financial institutions. The paper s conclusion is: "Our results suggest that changes in both cortisol and testosterone could play a destabilizing role in financial markets through increased risk taking behavior, acting via different behavioral pathways." Dr. Allegra (Fexofenadine) Ed Roberts, from the department of medicine at the UK s Imperial College London and one of the lead authors of the study, says: "Our aim is to understand more about what these hormones do. Cilostazol without Rx Then we can look at the environment in which traders work, and think about whether it s too stressful or too competitive. "These factors could be affecting traders hormones and having an impact on their decision-making." Saliva samples Some 142 volunteers, male and female, participated in the study, giving saliva samples for the measurement of the two hormones. They played an asset trading game in groups of around 10. Diltiazem (Diltiazem Hcl) without prescription Those who had higher levels of cortisol were more likely to take risks, and high levels in the group were associated with instability in prices. In a second experiment, 75 young men were given either cortisol or testosterone before playing the game. Buy Liver online They were tested once while on the hormone and once while on a placebo. Both hormones had an effect toward greater risk-taking in investments. http://allergy-opinion.blogspot.com Cortisol appeared to directly affect volunteers preference for riskier assets, while testosterone seemed to increase optimism about how prices would change in the future. Dr. Roberts says: "The results suggest that cortisol and testosterone promote risky investment behavior in the short run. "We only looked at the acute effects of the hormones in the lab. It would be interesting to measure traders hormone levels in the real world, and also to see what the longer term effects might be." Written by Markus MacGill

Benefits of extracurricular sports extend into the classroom

Extracurricular sports have long been promoted as a way of keeping children healthy, but new research suggests they could also provide benefits in the classroom, helping children remain engaged and disciplined. The study suggests an association between physical activity and self-regulation from kindergarten to fourth grade. The study, published in the American Journal of Health Promotion, found that children who regularly participated in structured sports were better at following instructions and remaining focused in the classroom than their peers by the time they reached fourth grade. "There is something specific to the sporting environment - perhaps the unique sense of belonging to a team, a special group with a common goal - that appears to help kids understand the importance of respecting the rules and honoring responsibilities," explains study author Linda Pagani of the University of Montreal, Canada. For the study, Pagani and colleagues analyzed data obtained from the Quebec Longitudinal Study on Child Development on 2,694 children born between 1997 and 1998. About Hard On (Sildenafil Citrate) with free prescription She explains the aims of the study: "Our goal was to answer two questions: firstly, does participation in extracurricular activities in kindergarten predict fourth-grade self-discipline, and secondly, do kindergarten self-discipline characteristics predict fourth-grade participation in sports?" Information was provided by both the teachers and parents of children in kindergarten, detailing the behavior of the children while in school and at home. About Atrovent (Ipratropium Bromide) with free prescription Four years later, when the children had reached fourth grade, the information-gathering exercise was repeated. Once they had obtained the data, the researchers took into account other factors that could have influenced their findings such as the children s physical fitness, parental education levels and how well the family unit functioned. The researchers found that children who participated in structured activities such as sports while at kindergarten were more likely to be involved in sports by the time they reached fourth grade. Buy Actigall (Ursodeoxycholic acid) with no prescription In contrast, participating in unstructured activities had no impact on the child s future. Extracurricular sports could prevent kids from being left behind "Across the board, we found that children who had better behavior in the kindergarten class were more likely to be involved in sport by age 10," reports Pagani. Buy Cevibid "Nonetheless, we found that those children who were specifically involved in team sports at kindergarten scored higher in self-regulation by the time they reached fourth grade." According to the researchers, sporting activities and attention skills are intrinsically linked, and school planning can use this association to the benefit of pupils. Elavil (Amitriptyline) without prescription Additionally, pupils deemed to be at risk of not getting enough exercise could be targeted to improve both obesity and school drop-out rates. "Programs to help parents develop their child s self-regulation skills and the availability of extracurricular sports programs as early as kindergarten could help decrease the risk of kids being left behind," Pagani suggests. The researchers hope that their findings can be of use to policymakers outside of schools as well, leading to improved access to parks and playgrounds for children and their families and to promoting active schools and communities as a whole. According to a report released this past December by the US Census Bureau, there are a large number of children that do not currently participate in extracurricular activities. Buy L-Proline online Although children were found to be more likely to participate in sports than other activities, only 57% of children aged 6-17 participate in at least one after-school extracurricular activity. The report identified household structure as a factor that influenced how likely a child was to be involved in extracurricular activities. http://asthmareview.wordpress.com Children whose parents were married and lived together were more likely to participate than children living with cohabiting parents or a single parent. Recently, Medical News Today reported on a study finding that when teenagers exercise like young children - in short bursts of intense activity - their health outcomes are improved. Written by James McIntosh